Vivimed Labs FY26 results filed under CIRP, auditor gives qualified opinion

Going ConcernQualified OpinionEmphasis Of MatterRevenue DeclinePat NegativeEbitda Margin CompressionResults View source PDF Explain this filing

VIVIMEDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹6.84

prior close

₹6.71

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%-0.3% vs market

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-1.9-1.6-0.3

Next day

-3.8-1.0-2.8

-5.7-2.6-3.1

-7.5-5.1-2.3

-9.2-6.1-3.1

-11.0-8.3-2.7

-14.3-6.4-8.0

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivimed Labs filed audited FY26 results (standalone and consolidated) under CIRP initiated April 15, 2026 by NCLT. Board powers suspended, IRP in charge. Standalone revenue Rs 310.32M vs Rs 311.03M prior year. Consolidated revenue fell to Rs 763.08M from Rs 1162.69M. Standalone net loss widened to Rs 1716.11M from Rs 314.96M. Auditor SVRL gave qualified opinion citing Rs 625.72M unrecorded interest, unconfirmed balances, and going concern doubts. Net worth is negative at minus Rs 1121.94M standalone.

Likely market impact

Negative net worth, qualified audit opinion, and active CIRP signal serious financial stress. Shareholders face restructuring risk and possible dilution or write-down.